Apremilast for the treatment of psoriasis

Bibliography

• Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 2009;60:218-24
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147-51
   PubMed Web of Science ®Google Scholar
• Van der Velden HM, Klaassen KM, van de Kerkhof PC, et al. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life. Dermatology 2014;229(2):76-82
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Nakajima K, Takaishi M, et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol 2014;135(2):445-53
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management o psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on biologics. J Am Acad Dermatol 2008;58:851-64
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ballanti E, Perricone C, et al. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013;12:599-606
   PubMed Web of Science ®Google Scholar
• Christophers E. Psoriasis–epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20
   PubMed Web of Science ®Google Scholar
• Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-8
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. J Am Acad Dermatol 2011;65:137-74
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303(1):1-10
   PubMed Web of Science ®Google Scholar
• Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol 2007;25:524-8
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
   PubMed Web of Science ®Google Scholar
• Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005;5:699-711
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012;44(12):1341-8
   PubMed Web of Science ®Google Scholar
• Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012;132(10):2320-31
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
   PubMed Web of Science ®Google Scholar
• Albanesi C, De Pita O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol 2007;25:581-8
   PubMed Web of Science ®Google Scholar
• Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol 2009;129:302-8
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Saraceno R, Chimenti MS, et al. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets 2014;18(5):513-25
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131(3):677-87
   PubMed Web of Science ®Google Scholar
• Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003;370:1-18
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55
   PubMed Web of Science ®Google Scholar
• Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009;52-1522-4
   Google Scholar
• Brezinski EA, Armstrong AW. Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. Semin Cutan Med Surg 2014;33:91-7
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-98
   PubMed Web of Science ®Google Scholar
• Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 2010;35:91-100
   PubMed Web of Science ®Google Scholar
• Houslay MD. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-19
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35
   PubMed Web of Science ®Google Scholar
• Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014;73(1):3-5
   PubMed Web of Science ®Google Scholar
• Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol 2013;38(6):573-88
   PubMed Web of Science ®Google Scholar
• Carretero G, Ferrandiz C, Dauden E, et al. BIOBADADERM Study Group. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol 2015;29(1):156-63
   PubMed Web of Science ®Google Scholar
• Novelli L, Chimenti MS, Chiricozzi A, et al. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev 2014;13:64-9
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Costanzo A, Chimenti MS, et al. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin Biol Ther 2008;8(3):363-70
   PubMed Web of Science ®Google Scholar
• Saraceno R, Bavetta M, Zangrilli A, et al. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. Expert Opin Biol Ther 2013;13(9):1325-34
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Trigoni A, et al. Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol 2012;4(3):320-3
   PubMedGoogle Scholar
• Gudjonsson JE, Johnston A, Ellis CN. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol 2012;67:139
   PubMed Web of Science ®Google Scholar
• Kaminska B, Swiatek-Machado K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol 2008;4:93-112
   PubMed Web of Science ®Google Scholar
• Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol 2015;95(2):133-9
   PubMed Web of Science ®Google Scholar
• Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep 2014;16:443
   PubMed Web of Science ®Google Scholar
• Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169:137-45
   PubMed Web of Science ®Google Scholar
• Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012;67:658-64
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014;26:2016-29
   PubMed Web of Science ®Google Scholar
• Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011;91(2):651-90
   PubMed Web of Science ®Google Scholar
• Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004;25:430-6
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006;109:238-45
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-75
   PubMed Web of Science ®Google Scholar
• O’Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004;25:158-63
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KYJ. Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-19
   PubMed Web of Science ®Google Scholar
• Claveau D, Chen SL, O’Keefe S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141[4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004;310:752-60
   PubMed Web of Science ®Google Scholar
• Conti M, Richter W, Mehats C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003;278:5493-6
   PubMed Web of Science ®Google Scholar
• Biorgo E, Tasken K. Role of cAMP Phosphodiesterase 4 in regulation of T-cell function. Crit Rev Immunol 2006;26:443-52
   PubMed Web of Science ®Google Scholar
• Christensen SB, Guider A, Forster CJ, et al. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J Med Chem 1998;41(6):821-35
   PubMed Web of Science ®Google Scholar
• Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2- methanesulfonylethyl]-1, 3-dioxo-2, 3-dihydro-1 H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor. J Med Chem 2009;52:1522-4
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Fabbri LM, Rabe KF, et al. Roflumilast in the treatment of COPD: a pooled safety analysis. Eur Respir J 2010;Abstract P4001
   Google Scholar
• Odingo JO. Inhibitors of PDE4: a review of recent patent literature. Exp Opin Ther Pat 2005;15:773-87
   Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67
   PubMed Web of Science ®Google Scholar
• Schett G, Sloan VS, Stevens RM, et al. Apremilast: A novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskeletal Dis 2010;2:271-8
   PubMedGoogle Scholar
• Gottlieb AB, Strober B, Krueger JK, et al. An open-label, single-arm pilot study in patient with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24:1529-38
   PubMed Web of Science ®Google Scholar
• Papp K, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013;27(3):e376-83
   PubMed Web of Science ®Google Scholar
• Reich K, Papp K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 1). Oral presented at: 71st Annual Meeting of the American Academy of Dermatology (AAD); 1 – 5 March 2013b, Miami Beach, FL, USA
   Google Scholar
• Reich K, Papp K, Leonardi C, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 21 – 25 March 2014, Denver, CO, USA
   Google Scholar
• Papp K, Reich K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 21 – 25 March 2014, Denver, CO, USA
   Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015;73(1):37-49
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 21 – 25 March 2014, Denver, CO, USA
   Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380(9843):738-46
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang K. Phosphodiesterase-4 as a terapeutic target. Drug Discov Today 2005;10:1503-19
   PubMed Web of Science ®Google Scholar
• Available from: http://www.otezla.com/wp-content/uploads/2014/05/otezla-prescribing-information.pdf
   Google Scholar
• Chimenti MS, Graceffa D, Perricone R. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 2011;10(10):636-40
   PubMed Web of Science ®Google Scholar
• Cush JJ, Dao KH. Malignancy risks with biologic therapies. Rheum Dis Clin North Am 2012;38:761-70
   PubMed Web of Science ®Google Scholar